Abstract Submission Deadline

Transcription

1 Abstract Submissin Guidelines Authrs are invited t submit abstracts fr the upcming 17 th Internatinal Myelma Wrkshp being held September 12-15, 2019 in Bstn, Massachusetts. During the prestigius biannual Internatinal Myelma Wrkshp (IMW), myelma experts frm arund the wrld gather t discuss basic, preclinical and clinical aspects in the bilgy and treatment f multiple myelma. The scientific prgram will include ral presentatins, cnsensus panels, debates n cntrversial and current arguments, and pster abstracts. Abstracts presenting new research and/r furthering existing studies in the bilgy and treatment f multiple myelma are encuraged. Be sure t cmplete all steps and t finalize the abstract submissin. Only finalized submissins will be evaluated. All abstracts will be blinded and peer reviewed. Abstracts will be selected based n the relevance f the tpic, the scientific merit, the quality f the study and the impact f the results n further studies and/r clinical practice, interest t IMW attendees and available space. Authrs will be ntified in late June 2019 if their abstract has been accepted fr presentatin at the Wrkshp. Presenting authrs will be required t register fr the 17 th Internatinal Myelma Wrkshp. The abstract submissin deadline is Friday, May 31, 2019, 11:59 pm ET. Imprtant Dates May 31, 2019 June 28, 2019 July 12, 2019 July 1-19, 2019 August 1, 2019 Abstract Submissin Deadline Abstract Ntificatin Abstract Acceptance Deadline Nte, if abstract is selected and an acceptance is nt received by this deadline, the abstract will autmatically be withdrawn. Late-Breaking Abstract Submissin Open (clses at 11:59 pm ET (GMT-5)) Late-Breaking Abstract Ntificatin Submissin Types Oral Abstract A limited number f high-ranking abstracts will be selected fr ral presentatin. Pster Abstract Presenters will make physical r electrnic psters t present during dedicated pster sessins. Presenters are required t be with their psters during the evening pster receptin times. 1 P a g e

2 Authrs and Presenters Include the name, address, and institutinal affiliatin and lcatin fr all c-authrs. There is n limit n the number f c-authrs. If an authr's name appears n mre than ne abstract, it must be identical n each abstract. The submitter must als identify the authr wh will present the abstract, which is limited t ne presenter. All presenters are required t disclse any financial and nn-financial cnflicts f interests s that cntinuing educatin may be prvided. This infrmatin will be required upn ntificatin f abstract acceptance in June An will AUTOMATICALLY be sent t each authr t lg in and verify their infrmatin. Authrs wh submit multiple abstracts shuld be prepared t make arrangements fr alternative presenters t attend in case mre than ne abstract is accepted and presentatin times verlap. Respnsibility f Abstract Submitters Submissin f an abstract cnstitutes a cmmitment by the authr(s) t present if accepted. Authrs are respnsible fr prviding a substitute presenter if the presenting authr is unable t attend. Encre abstracts are permitted, hwever new data is encuraged and scring will depend n expanding n what was presented at ther meetings. By submitting an abstract, the authrs certify that s/he has written cnsent fr use f any recgnizable phtgraphs in psters r presentatins. All riginal research invlving human subjects r animal studies must adhere t internatinally accepted standards fr the cnduct f research. Human subject and animal research shuld be apprved by a reginally apprpriate versight mechanism, such as an Institutinal Review Bard (IRB) r Animal Care and Use Cmmittee. Respnsibility f Abstract Presenters Presenting the abstract, if accepted. Assuring that all apprpriate financial and nn-financial relatinship disclsures have been made. Disclsure f financial relatinships with cmmercial entities is required fr the presenting authr and his/her spuse and institutin. Annuncing the disclsures befre the presentatin f the abstract. Lgging in t the abstract site t RSVP acceptance f the presentatin and review the presentatin guidelines, if accepted. Presenters must register fr the 17 th IMW and are respnsible fr all registratin fees and persnal expenses related t the meeting. 2 P a g e

3 Late-Breaking Abstracts Submissin Windw: July 1 19, 2019, 11:59 pm Eastern Standard Time (GMT-5) This categry is intended fr studies that were nt available at the time f the abstract deadline such as clinical trials where the interim analysis is planned fr after the abstract deadline. These abstracts are nt limited t clinical trials but shuld include studies with imprtant findings which will impact the field. A limited number f these abstracts will be selected fr ral presentatin, with the remaining presented as psters if they meet the selectin criteria f high impact. Abstract Embarg Plicy In cmpliance with the Securities and Exchange Cmmissin s Regulatin FD (Fair Disclsure), accepted abstracts are made available nline in advance f the Wrkshp. These abstracts will als be published as a special supplement t the Clinical Lymphma and Myelma jurnal. Cverage f infrmatin that ges beynd the fur crners f the abstract (e.g., additinal analysis, cmmentary, r updated infrmatin frm thse individuals and cmpanies invlved in the study) is embarged accrding t the fllwing criteria: Fr ral presentatins: the embarg lifts at the start time f the sessin in which the presentatin is being made. Fr pster presentatins: the embarg lifts when the pster sessin cntaining the pster pens fr viewing in the mrning (i.e., when the psters pens that day). Fr publicatin-nly abstracts: the embarg lifts when the abstract is first made publicly available in the jurnal f Clinical Lymphma and Myelma. These abstracts are nt presented at the IMW. Abstracts selected fr presentatin at the 17 th IMW will be available nline Tuesday, August 13, 2019, 4:00 p.m. EDT. Nte: The abstract embarg still applies; hwever, abstracts are made available t attendees t assist in creating their itineraries fr the meeting. 3 P a g e

4 Abstract Elements Belw is a list f the sectins required fr all abstracts. D nt include any identifying infrmatin in the bdy r title f the abstract. Title - The title shuld be brief (150 characters), but lng enugh t identify clearly the nature f the presentatin. Omit authr names, degrees, titles and institutinal appintments. D nt include any identifying infrmatin in the title. Abstract Type Oral Abstract A limited number f high-ranking abstracts will be selected fr ral presentatin (7.5 minutes). Pster Abstract Presenters will make physical r electrnic psters t present during dedicated pster sessins. Presenters are required t be with their psters during the evening pster receptin times. Authrs Identify (r add) the primary authr and any additinal c-authrs. There is n limit t the number f c-authrs. Abstract Cntent & Requirements Blind the bdy and title f the abstract apprpriately. Any identifying infrmatin in the cntent r title fields will be cause fr rejectin. Please nte that the abstract submissin system des nt accept images r graphics. There is n specific required frmat fr abstract cntent. Hwever, the rganizatin f all abstracts will be taken int cnsideratin during the grading prcess. Yu may elect t rganize yur abstract cntent int Intrductin /Backgrund, Methds, Results, and Cnclusin. Authrs shuld be aware that abstracts will be published as submitted withut cpyediting. If accepted all spelling errrs, grammar, misspelled authr name/credentials, will be published as submitted. Character Allwances: Title: Up t 150 characters, including spaces. Bdy: Up t 3,000 characters, cumulative, including spaces. Abstract Track Chse the categry that best characterizes yur abstract. Treatment f Newly Diagnsed Myelma- Transplant Eligible Treatment f Newly Diagnsed Myelma- Nn-Transplant Treatment f Previusly Treated Myelma Transplant and Maintenance Strategies Other Plasma Cell Disrders and Amylidsis Antibdy Based Treatment Appraches Immuntherapeutic Appraches t Myelma Myelma Nvel Drug Targets 4 P a g e

5 Myelma Nvel Agents Myelma Genmics Myelma Signaling Myelma Bne Disease Myelma Micrenvirnment Myelma MRD Assessment Keywrds Chse up t three (3) keywrds fr yur abstract. Search fr keywrds befre adding a new ne t prevent duplicate keywrds. Additinal Infrmatin Answer the additinal questins fr each submitted abstract. Preferred Presentatin Frmat Oral r Pster If yur preferred frmat is ral and yur abstract is selected as a pster, identify if yu wuld like yur abstract withdrawn First time submitting an abstract t the IMW meeting If yu wuld like t als be cnsidered fr the Nursing Sympsium, held cncurrently with IMW. If yu wuld like the abstract t be cnsidered fr the IMS Awards fr Exemplary Abstracts. Eligibility criteria lcated here. Review Prcess All abstracts will be blinded and peer reviewed accrding t specific criteria. Pster presentatins will be selected n the basis f tpic, quality f material, and available space. If a significant number f attendees culd btain r have btained this infrmatin elsewhere, it may cause yur abstract t receive a lwer rating. Abstracts will be assessed based n the fllwing pints: Is the tpic apprpriate fr the 17 th IMW? Des the research meet apprpriate scientific merit? Is the study and data f high quality and is the infrmatin well rganized? Is there an impact f the results n further studies and r clinical practice? Withdrawal requests Abstracts may be withdrawn in the abstract submissin system befre July 19, 2019 t avid publicatin in the prgram. If it is after that time, please imwabstracts@sparginc.cm. Cntact Us Visit the 17 th IMW website at bstn.php r us at imwabstracts@sparginc.cm fr mre infrmatin. 5 P a g e